- |||||||||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Giazo (balsalazide disodium tablet) / Bausch Health
Journal: Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database. (Pubmed Central) - Oct 29, 2024
Disproportionality analysis revealed that the top 5 drugs by ROR were phendimetrazine tartrate (ROR 104.64), trimethoprim?+?sulfamethoxazole (ROR 67.65), aldesleukin (ROR 52.67), mesalazine (ROR 49.73), and balsalazide disodium (ROR 45.26)...Through comprehensive analysis of the FAERS database, our study identified drugs with a strong signal for myocarditis that are not currently indicated on their labels. The findings suggest that the potential risk of myocarditis associated with these medications is significant and warrants close monitoring in clinical practice.
- |||||||||| Bontril (phendimetrazine extended release) / Bausch Health
Clinical, Journal: Effect of JumpstartMD, a Commercial Low-Calorie Low-Carbohydrate Physician-Supervised Weight Loss Program, on 22,407 Adults. (Pubmed Central) - May 20, 2021
JumpstartMD produced generally greater weight loss than published reports for other real-food and prepackaged-meal commercial programs and somewhat greater or comparable losses to meal replacement diets. A one-on-one medically supervised program that emphasized real low-carbohydrate foods produced effective weight loss, particularly in those attending ≥75% of their weekly appointments.
- |||||||||| methylphenidate tablet / Generic mfg.
Clinical, Journal: Evaluation of pharmaceutical abuse and illicit drug use in South Korea by wastewater-based epidemiology. (Pubmed Central) - Apr 27, 2021
The mean estimated meperidine and cis-tramadol (opioid) consumption rates were 120 and 27.5 mg d (1000 people), respectively, and were 8.2 and 1.7 times higher, respectively, than the consumption rates found in 2013. Methylphenidate was detected in the influent and effluent samples at mean concentrations of 2.7 and 2.6 ng L, respectively, but the methylphenidate consumption rate could not be estimated because of the low excretion rate for humans (<1%).
- |||||||||| TRENDS OF SLEEVE GASTRECTOMY AND POST-OPERATIVE WEIGHT LOSS PHARMACOTHERAPY OVER 10 YEARS: A LARGE DATABASE STUDY (S105bc) - May 19, 2020 - Abstract #SSAT2020SSAT_294;
We studied the individuals who were prescribed at least one weight loss medication [orlistat, liraglutide (Saxenda), lorcaserin, phentermine-topiramate, bupropion-naltrexone, phentermine, diethylpropion, benzphetamine, and phendimetrazine] at least 7 days after the procedure...Despite the growing trend, sleeve gastrectomy and post-operative anti-obesity pharmacotherapy are underutilized in the US with < 1% of obese adults undergoing SG out of which < 5% being prescribed anti-obesity pharmacotherapy. Further large-scale studies are required to explore interventions to increase the utilization of these therapies.
- |||||||||| TRENDS OF SLEEVE GASTRECTOMY AND POST-OPERATIVE WEIGHT LOSS PHARMACOTHERAPY OVER 10 YEARS: A LARGE DATABASE STUDY () - May 4, 2020 - Abstract #DDW2020DDW_4094;
We studied the individuals who were prescribed at least one weight loss medication [orlistat, liraglutide (Saxenda), lorcaserin, phentermine-topiramate, bupropion-naltrexone, phentermine, diethylpropion, benzphetamine, and phendimetrazine] at least 7 days after the procedure...Despite the growing trend, sleeve gastrectomy and post-operative anti-obesity pharmacotherapy are underutilized in the US with < 1% of obese adults undergoing SG out of which < 5% being prescribed anti-obesity pharmacotherapy. Further large-scale studies are required to explore interventions to increase the utilization of these therapies.
- |||||||||| Journal: Pharmacological management of obesity. (Pubmed Central) - Nov 28, 2018
Medications for obesity can be simply categorized as FDA approved short-term use (diethylproprion, phendimetrazine, benzphetamine, and phentermine) and long-term use (orlistat, phentermine/topiramate ER, lorcaserin, naltrexone/bupropion ER and liraglutide)...Finally, weight-centric prescribing is also an important component to pharmacological management of obesity. It warrants that healthcare providers thoroughly review their patients' medication lists to determine if any of these agents could be contributing to weight gain.
- |||||||||| phendimetrazine extended release / Generic mfg.
Trial primary completion date: BED IN 31: Reinforcing Effects of Cocaine During Phendimetrazine Maintenance (clinicaltrials.gov) - Apr 6, 2017
P1, N=36, Recruiting,
It warrants that healthcare providers thoroughly review their patients' medication lists to determine if any of these agents could be contributing to weight gain. Trial primary completion date: Jul 2018 --> Nov 2018
- |||||||||| Trial completion, Trial primary completion date: Phendimetrazine and Cocaine (clinicaltrials.gov) - May 11, 2016
P0, N=10, Completed,
Trial primary completion date: Jul 2018 --> Nov 2018 Recruiting --> Completed | Trial primary completion date: May 2016 --> Dec 2015
- |||||||||| Bontril (phendimetrazine extended release) / Bausch Health
Clinical: Phendimetrazine and Cocaine (clinicaltrials.gov) - Sep 8, 2014
P0, N=12, Recruiting,
|
